NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Simon Kraler and Colleagues’ New Work on JCAD: Targeting Impaired Fibrinolysis to Address Post-ACS Residual Risk
Simon Kraler/LinkedIn
Dec 24, 2025, 22:50

Simon Kraler and Colleagues’ New Work on JCAD: Targeting Impaired Fibrinolysis to Address Post-ACS Residual Risk

Simon Kraler, ESC Young Cardiovascular Professionals Committee Member at European Society of Cardiology, posted on LinkedIn:

“Residual risk: is it time to move beyond LDL-c and inflammation?

Despite guideline-directed lipid lowering and anti-inflammatory therapy, patients with a recent ACS remain at 𝐯𝐞𝐫𝐲 𝐡𝐢𝐠𝐡 𝐢𝐬𝐜𝐡𝐚𝐞𝐦𝐢𝐜 𝐫𝐢𝐬𝐤.

Based on GWAS and mechanistic data, we hypothesized that JCAD (‘Junctional Protein Associated with Coronary Artery Disease’) on chromosome 10 might represent the missing link.

In our newly published European Heart Journal study, JCAD independently predicted 1-year MACE in patients with residual lipid risk, inflammatory risk, or both – notably independent of LDL-c and hs-CRP
JCAD = impaired endogenous fibrinolysis and high MACE risk, with similar results obtained during external validation.
JCAD may represent a novel therapeutic target to address residual risk after a recent ACS.

Full paper

Title: The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk

Authors: Simon Kraler, Luca Liberale, Amedeo Tirandi, Margherita Moriero, Yifan Wang, Mohamed Farag, Federico Carbone, Maria B Bertolotto, Valentina Pusterla, Davide Ramoni, Stefano Ministrini, Yustina M Puspitasari, Francesco Bruno, Lorenz Räber, Davide Di Vece, Christian Templin, Olivier Muller, François Mach, Filippo Crea, Giovanni G Camici, Tetiana Lapikova-Bryhinska, Alexander Akhmedov, Arnold von Eckardstein, Diana A Gorog, Fabrizio Montecucco, Thomas F Lüscher

Simon Kraler and Colleagues' New Work on JCAD: Targeting Impaired Fibrinolysis to Address Post-ACS Residual Risk

Special thanks to the colleagues and friends at University of Genoa, King’s College London, University of Zurich, CHUV | Lausanne university hospital, Universitätsspital Zürich, HUG – Hopitaux Universitaires de Genève and Insel Gruppe.

Thank you Thomas F. Lüscher, Luca Liberale, Giovanni G Camici, Diana Gorog, Lorenz Räber, Davide Di Vece, Yifan Wang, Francesco Bruno and all!”

Simon Kraler and Colleagues' New Work on JCAD: Targeting Impaired Fibrinolysis to Address Post-ACS Residual Risk

Discover the latest in Hemostasis Today.

Alexander Akhmedov Amedeo Tirandi Arnold von Eckardstein Christian Templin CHUV | Lausanne university hospital Davide Di Vece Davide Ramoni Diana A. Gorog Diana Gorog Fabrizio Montecucco Federico Carbone Filippo Crea Francesco Bruno François Mach Giovanni G Camici GWAS Health Hemostasis Hemostasis Today HUG - Hopitaux Universitaires de Genève Insel Gruppe JCAD ('Junctional Protein Associated with Coronary Artery Disease') King's College London Lorenz Räber Luca Liberale Margherita Moriero Maria B Bertolotto mechanistic data Medicine Mohamed Farag Olivier Muller Simon Kraler Stefano Ministrini Tetiana Lapikova-Bryhinska Thomas F Lüscher thrombosis Universitätsspital Zürich University of Genoa University of Zurich Valentina Pusterla Yifan Wang Yustina M Puspitasari
NewsFeed